Last reviewed · How we verify
Acute Lymphoblastic Leukemia (ALL)
Approved treatments
- Doxorubicin Hydrochloride · Pfizer Inc.
Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication. - Asparlas · Servier Pharma Llc
Asparlas depletes asparagine, an amino acid that cancer cells rely on for growth.
Clinical guidelines
- FDA label — any
Doxorubicin Hydrochloride Injection is indicated for the treatment of acute lymphoblastic leukemia. - FDA label — any
Doxorubicin Hydrochloride Injection is indicated for the treatment of acute myeloblastic leukemia. - FDA label — any
Doxorubicin Hydrochloride Injection is indicated for the treatment of Hodgkin lymphoma. - FDA label — any
Doxorubicin Hydrochloride Injection is indicated for the treatment of non-Hodgkin lymphoma. - FDA label — any
Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic breast cancer. - FDA label — any
Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic Wilms' tumor. - FDA label — any
Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic neuroblastoma. - FDA label — any
Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic soft tissue sarcoma. - FDA label — any
Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic bone sarcoma.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: